Careers  |  Sign In  |  Register  |   Twitter

Omalizumab is Potential Treatment for Chronic Idiopathic Urticaria

Chronic idiopathic urticaria causes itchy hives that have no apparent external cause, and many patients do not respond to treatment with H1-antihistamines. A new study in The New England Journal of Medicine investigates the usefulness and safety of omalizumab, an add-on therapy for allergic asthma, in patients with chronic idiopathic urticaria that do no respond to H1-antihistamines. “At week 12, the mean (±SD) change from baseline in the weekly itch-severity score was −5.1±5.6 in the placebo group, −5.9±6.5 in the 75-mg group (P=0.46), −8.1±6.4 in the 150-mg group (P=0.001), and −9.8±6.0 in the 300-mg group (P<0.001).”

Read it in NEJM.